These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29696160)

  • 21. Optimization of EWOC principle in BLRM design for phase 1 oncology trials.
    Guo X; Kent S; Maity A; Zhong W
    J Biopharm Stat; 2024 Apr; ():1-17. PubMed ID: 38562014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
    Wages NA; Fadul CE
    Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the relative efficiency of model-assisted designs: a conditional approach.
    Lin R; Yuan Y
    J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives.
    Sverdlov O; Wong WK
    Ther Innov Regul Sci; 2014 Sep; 48(5):601-612. PubMed ID: 30231452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
    Guo W; Ji Y; Li D
    J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations.
    Cunanan KM; Koopmeiners JS
    Contemp Clin Trials; 2018 Aug; 71():162-172. PubMed ID: 29936124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of loss functions: A note on the evolution of the Toxicity Probability Interval design.
    Siegel J
    Contemp Clin Trials Commun; 2021 Jun; 22():100694. PubMed ID: 34027221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
    Rossoni C; Bardet A; Geoerger B; Paoletti X
    Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
    Yuan Z; Chappell R
    Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.
    Xue X; Foster MC; Ivanova A
    J Biopharm Stat; 2019; 29(4):625-634. PubMed ID: 31251112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effects of design parameters on the performances of phase I trial designs.
    Zhu Y; Hwang WT; Li Y
    Contemp Clin Trials Commun; 2019 Sep; 15():100379. PubMed ID: 31193764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials.
    Lin X; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):993-1005. PubMed ID: 33225828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.